P1128 Course of patients with Ulcerative colitis who have achieved disease clearance from the moment of diagnosis
Authors: Rustamzade A , Hacıalioglu C , Duman O , Topuz S , Uzun Z , Telli P , Gurbanov A , Yağlı M A , Dağcı G , Genç S , Çavuş B , Çİfcibaşı Örmeci A , Akyüz F , Demir K , Beşışık S F , Kaymakoglu S 
Published: January 2025

Background

In patients with ulcerative colitis, histological healing is associated with better clinical outcomes1. Therefore,histological remission as the treatment target is advocated. observational studies2,3 have shown that patients in endoscopic, histological remission have longer relapse-free survival, reduced hospitalization rates, corticosteroid use rates.

Methods

Demographic information, laboratory findings, clinical courses of patients with ulcerative colitis who had disease clearance, were evaluated retrospectively for 5 years. The files of 529 patients with ulcerative colitis were scanned, patients who had not achieved disease clearance, had a history of surgery, were not followed regularly, were &lt;5 years old were excluded. 87 patients were included in this study. The validated Nancy histological index was used to assess histological disease activity.

Results

A total of 87 patients with Ulcerative Colitis, 51 of whom were male. The mean age was 54.1±13.5 years. The mean age of the patients at diagnosis was 38.9±13.6 years. The mean follow-up period was 14.5±7.7 years. The mean disease age was 15.6±7.8 years. Only 1 patient had a family history. 5 (5.7%) patients had pANCA positivity. 14 (16%) patients had extraintestinal involvement (ankylosing spondylitis, erythema nodosum, sacroiliitis, arthritis, uveitis). Current disease involvement was E1 in 11 (12.6%) patients, E2 in 45 (51.7%) patients, and E3 in 31 (35.7%) patients. Mayo endoscopic subscore was 0 in 45 (51.7%) patients; Mayo endoscopic subscore was 1 in 42 (48.3%) patients. In maintenance treatment, 50 (57.5%) were receiving only oral/topical 5-ASA, 37 (42.5%) were receiving azathioprine and 5-ASA combination. Remission was achieved in 72 (82.8%) patients with conventional treatment, and only 15 (17.2%) were receiving biological treatment. During the course of the disease, 29 (33.3%) patients required ≥1 steroid. No attacks were observed in 69 (79.3%) patients in the last 5 years. The rate of achieving remission was found to be 16% in 529 patients.

Conclusion

Although the rate of achieving deep remission in ulcerative colitis is low, remission rates are high in patients with rectal or left colon involvement at the time of diagnosis.

References

1.Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19. PMID: 33359090.

2.Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol. 2011 May-Jun;17(3):194-8. doi: 10.4103/1319-3767.80383. PMID: 21546723; PMCID: PMC3122090.

3.Bessissow T, Lemmens B, Ferrante M, Bisschops R, Van Steen K, Geboes K, Van Assche G, Vermeire S, Rutgeerts P, De Hertogh G. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012 Nov;107(11):1684-92. doi: 10.1038/ajg.2012.301. Epub 2012 Nov 13. PMID: 23147523.